Victoza dosage and titration schedule

Every product in this class begins below its working dose and climbs on a schedule. Victoza is no exception, and the shape of that climb explains most of what people find confusing about their first few months — why the early weeks feel like nothing is happening, why a bad week follows every increase, and why the number on the pen is not the point.

Maintenance dose: 1.2 mg or 1.8 mg daily.

What each rung is actually for

• 0.6 mg daily — week 1. Adaptation only — not effective for glucose control.
• 1.2 mg daily — week 2 onward. First treatment dose.
• 1.8 mg daily — after ≥1 week. Maximum dose, if further control is needed.

Why the schedule moves at this pace

Each step lasts a week, because liraglutide reaches a stable level in about three days — the ladder can move quickly because the pharmacology allows it. A drug reaches a stable blood level after roughly five half-lives. Victoza has a half-life of ~13 hours and reaches steady state in about 3 days.

Move up before that point and you are stacking a new dose on top of a level that has not finished rising. The nausea that follows is not evidence of a bad reaction to the medicine — it is a symptom of an impatient schedule. The arithmetic behind steady state is here.

The timeline in practice

At the minimum pace, reaching the top of the Victoza ladder takes about 2 weeks. In practice it usually takes longer, because steps get extended when side effects are still settling, and because many people stop climbing before the maximum.

That last point is worth dwelling on. The highest dose is a ceiling, not a target. 1.2 mg or 1.8 mg daily. Reaching a dose that works, and staying on it, is the outcome that matters — not arriving at the top of the chart.

When the ladder should slow down

The schedule is a default, not an obligation. Prescribers routinely hold a step for six or eight weeks instead of four when the gut is still adapting. There is no penalty for a slower climb and no clinical prize for a fast one.

Trials make the case concretely: gradual escalation cut the share of people who stopped treatment because of gastrointestinal side effects to a small fraction of what it was when full doses were given from the start. The slow ladder is not excessive caution — it is the reason the treatment remains usable at all.

Going back down

Stepping down a rung is a normal clinical move, not a failure. If a dose is producing side effects that do not settle within a few weeks, returning to the previous dose and holding there longer is often more productive than pushing through. The medicine you are still taking in six months is worth more than the dose you reached in six weeks.

Switching from another GLP-1

Doses are not interchangeable between molecules. There is no conversion factor between semaglutide and tirzepatide, or between either and liraglutide, and moving across without re-escalating reproduces the worst of a first escalation. A switch normally means starting the new product near the bottom of its own ladder, even if you were at the top of the previous one.

Dose and results

Higher doses produce larger average effects in trials, but the relationship is not linear and it is not uniform across people. Some people respond strongly at an intermediate dose and gain little from further increases; others need the upper rungs. This is one of the genuine reasons the ladder exists — it lets you find where you land instead of assuming.

What to track while you are climbing

The ladder is the period when the most useful information is generated and the most of it is lost. Four things are worth writing down, because none of them is reliably remembered four weeks later:

• Which rung you are on and the date you started it. This is the single most common thing people cannot answer at an appointment.
• Which day symptoms peaked after each increase. Two or three cycles reveal your own pattern, which is more useful than any average.
• Whether a symptom settled by week three. That is the question that decides whether a dose is genuinely tolerable or merely survivable.
• Weight as a trend, not a reading. Daily weight swings by more than a week of fat loss; only the four-week line means anything.

Questions worth asking at your next appointment

Consultations are short, and the questions that matter are easy to forget in the room. These four are worth having ready:

• What dose are we aiming for, and what would make us stop below it?
• If this step is hard, would you rather I hold here or step back?
• How long do we give this before deciding whether it is working?
• What symptom would make you want to hear from me before the next appointment?

The last one is the most important and the least often asked. Knowing in advance which symptoms warrant an unscheduled call removes the guesswork at the moment you are least able to do it.

Where this fits

This page covers one product. Three things about GLP-1 treatment are the same whichever product you are on, and they explain most of what happens month to month:

• The mechanism. Almost every side effect and every benefit traces back to the same three actions — insulin release, a slower stomach, and appetite signalling in the brain.
• The arithmetic. Half-life explains the weekly schedule, the slow first month, the forgiving missed-dose window, and why stopping is gradual whether you intend it to be or not.
• What you lose. Weight lost quickly, on low protein and without resistance training, includes a meaningful share of lean tissue. This is the least discussed part of the treatment and the one with the longest consequences.

Common questions

What is the difference between Victoza and Saxenda?

The same molecule under two labels. Victoza® stops at 1.8 mg daily for glucose control; Saxenda® continues to 3 mg for weight management. They are not interchangeable prescriptions even though the drug is identical.

How quickly do I reach the Victoza maintenance dose?

One week at 0.6 mg, then 1.2 mg — so most people are on a treatment dose within a fortnight. It is the shortest escalation in the class.